Are you Dr. Brudno?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 10 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
600 N Wolfe St
Park 307
Baltimore, MD 21287Phone+1 404-803-3741- Is this information wrong?
Summary
- Dr. Jennifer Brudno, MD is a hematologist in Baltimore, Maryland. She is currently licensed to practice medicine in Maryland and District of Columbia.
Education & Training
Emory University School of MedicineClass of 2010
Johns Hopkins UniversityResidency, Internal Medicine
National Institutes of Health Clinical CenterFellowship, Medical Oncology- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology
Certifications & Licensure
DC State Medical License 2013 - 2024
MD State Medical License 2013 - 2014- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain.Mikkilineni, L., Natrakul, D., Lam, N., Manasanch, E., Mann, J., Weissler, K., Wong, N., Brudno, J., Goff, S., Yang, J., Ganaden, M., Patel, R., Zheng, Z., Gartner, J....> ;Molecular Therapy. 2024 Feb 7
- 1 citationsTransient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial.Jennifer N Brudno, Danielle A Natrakul, Nisha Patel, Roberto Maass-Moreno, Mark A Ahlman, Lekha Mikkilineni, Jennifer Mann, David F Stroncek, Steven L Highfill, Genevi...> ;Blood Advances. 2024 Feb 13
- Limited utility of chimeric antigen receptor (CAR) T-cell retreatment: experience with a human anti-CD19 CAR.Jennifer N Brudno, James N Kochenderfer> ;Bone Marrow Transplantation. 2023 Oct 1
- Join now to see all
Press Mentions
BCMA-Targeting CAR T-cell Therapy Shows High Response Rate in Pretreated MyelomaDecember 1st, 2018
CAR-T Tx Shifts into First Gear in Lung CancerOctober 7th, 2018- Does CAR T-cell Therapy Induce Remission Following AlloHCT in Patients with B-cell Malignancies?April 28th, 2016
